Please Wait
Applying Filters...
menu
    • menu
    TAPI, a leading global supplier of APIs, provides over 350 products and customized CDMO solutions for every stage of development.

    Virtual Booth

    Contact Supplier

    Your reliable CDMO partner - agile, scalable, top-quality Small Molecule API & HPAPI solutions from concept to market

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2025-11-24

    Virtual Booth

    An Enquiry

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    Bachem Group is a public, innovation-driven company specializing in the development and manufacturing of peptides and oligonucleotides.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    An Enquiry

    Menu

    Edotreotide

    ACTIVE PHARMA INGREDIENTS

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    ITM Reveals Higher Response Rates Of (ITM-11) Vs. Everolimus
    ITM Reveals Higher Response Rates Of (ITM-11) Vs. Everolimus

    25 Oct 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/10/25/3174139/0/en/ITM-Announces-Analyses-from-Phase-3-COMPETE-Data-Showing-Higher-Objective-Response-Rates-with-n-c-a-177Lu-edotreotide-ITM-11-vs-Everolimus-Across-Subgroups-of-Patients-with-GEP-NET.html

    GLOBENEWSWIRE
    25 Oct 2025
    Share Share
    ITM’s Ph3 COMPETE Shows Higher ORR for ITM-11 vs Everolimus
    ITM’s Ph3 COMPETE Shows Higher ORR for ITM-11 vs Everolimus

    18 Oct 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/10/18/3168949/0/en/ITM-Announces-Phase-3-COMPETE-Data-Demonstrating-a-Statistically-Significant-Higher-Objective-Response-Rate-with-n-c-a-177Lu-edotreotide-ITM-11-vs-Everolimus-in-Patients-with-Gastr.html

    GLOBENEWSWIRE
    18 Oct 2025
    Share Share
    Methodist’s Generics Gallium68 Edotreotide Receive Approval in US
    Methodist’s Generics Gallium68 Edotreotide Receive Approval in US

    10 Oct 2025

    // FDA

    https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=218845

    FDA
    10 Oct 2025
    Share Share
    ITM Presents Ph3 COMPETE Data On 177Lu-edotreotide In GEP-NETs
    ITM Presents Ph3 COMPETE Data On 177Lu-edotreotide In GEP-NETs

    08 Oct 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/10/08/3163143/0/en/ITM-Presents-Dosimetry-Data-from-Phase-3-COMPETE-Trial-Supporting-Favorable-Efficacy-and-Safety-Profile-with-n-c-a-177Lu-edotreotide-ITM-11-in-Patients-with-Gastroenteropancreatic-.html

    GLOBENEWSWIRE
    08 Oct 2025
    Share Share
    ITM Presents Study Design of COMPOSE Phase III Trial with ITM-11
    ITM Presents Study Design of COMPOSE Phase III Trial with ITM-11

    19 Jan 2022

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20220119005075/en

    BUSINESSWIRE
    19 Jan 2022
    Share Share
    Eight Medicines win CHMP Nod
    Eight Medicines win CHMP Nod

    18 Oct 2016

    // Selina McKee PHARMATIMES

    http://www.pharmatimes.com/news/eight_medicines_win_chmp_nod_1167254

    Selina McKee PHARMATIMES
    18 Oct 2016
    Share Share